Once a drug lost primary patent protection or hit a certain age, it was managed for steady — if declining — cash flow with ...

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a ...

The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.

The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Makary’s exit ends a turbulent run marred by leadership upheaval, mass layoffs, political pressure and public spats with ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese ...

One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...

The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.

Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA ...